Search Result

Results for "

Doxorubicin

" in MedChemExpress (MCE) Product Catalog:

By Targets:	ADC Cytotoxin (8) ADC Linker (1) Adrenergic Receptor (5) Akt (1) Aldose Reductase (1) AMPK (3) Angiotensin-converting Enzyme (ACE) (1) Antibiotic (7) Apoptosis (26) Autophagy (15) Bacterial (8) Bcl-2 Family (2) BCRP (2) Caspase (2) DNA-PK (2) DNA/RNA Synthesis (4) Drug-Linker Conjugates for ADC (4) EGFR (1) Endogenous Metabolite (5) Endothelin Receptor (1) Epigenetic Reader Domain (1) ERK (2) Ferroptosis (2) Fungal (3) G-quadruplex (2) GnRH Receptor (1) HBV (3) HDAC (1) Histone Acetyltransferase (1) Histone Methyltransferase (1) HIV (3) ICMT (1) IKK (1) Interleukin Related (1) Isotope-Labeled Compounds (5) Keap1-Nrf2 (4) MAP3K (1) MAP4K (1) mGluR (1) Mitophagy (3) MMP (2) mTOR (1) NF-κB (1) NO Synthase (1) NOD-like Receptor (NLR) (1) Organoid (1) P-glycoprotein (11) Parasite (1) PI3K (1) Pim (1) Proton Pump (6) PTEN (1) Reactive Oxygen Species (4) ROCK (1) Survivin (1) TGF-beta/Smad (1) Toll-like Receptor (TLR) (1) Topoisomerase (16)
By Research Areas:	Cancer (79) Cardiovascular Disease (10) Endocrinology (3) Infection (11) Inflammation/Immunology (12) Metabolic Disease (1) Neurological Disease (1)
Click Chemistry:	Azide (1)

Inhibitors & Agonists

Fluorescent Dye

Biochemical Assay Reagents

Peptides

Inhibitory Antibodies

Natural
Products

Isotope-Labeled Compounds

Click Chemistry

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-116063

Doxorubicin-SMCC	Drug-Linker Conjugates for ADC	Cancer
Doxorubicin-SMCC is a agent-linker conjugate for ADC. Doxorubicin-SMCC contains a non-cleavable ADC linker and a DNA topoisomerase II inhibitor Doxorubicin .

HY-15142

Doxorubicin hydrochloride Maximum Cited Publications 364 Publications Verification Hydroxydaunorubicin hydrochloride	Topoisomerase ADC Cytotoxin AMPK Autophagy Apoptosis HIV HBV Mitophagy Antibiotic Bacterial	Infection Cancer
Doxorubicin (Hydroxydaunorubicin) hydrochloride, a cytotoxic anthracycline antibiotic, is an anti-cancer chemotherapy agent. Doxorubicin hydrochloride is a potent human DNA topoisomerase I and topoisomerase II inhibitor with IC₅₀s of 0.8 μM and 2.67 μM, respectively. Doxorubicin hydrochloride reduces basal phosphorylation of AMPK and its downstream target acetyl-CoA carboxylase. Doxorubicin hydrochloride induces apoptosis and autophagy .

HY-15142A

*Doxorubicin* Hydroxydaunorubicin	ADC Cytotoxin Antibiotic Bacterial Topoisomerase AMPK HIV Autophagy Mitophagy Apoptosis HBV	Infection Cancer
Doxorubicin (Hydroxydaunorubicin), a broad-spectrum anthracycline antibiotic with cytotoxic properties, is an anti-cancer chemotherapy agent. Doxorubicin has fluorescence properties. Doxorubicin inhibits topoisomerase II with an IC₅₀ of 2.67 μM, thus stopping DNA replication. Doxorubicin reduces basal phosphorylation of AMPK and its downstream target acetyl-CoA carboxylase. Doxorubicin induces apoptosis and autophagy . Doxorubicin inhibits human DNA topoisomerase I with an IC₅₀ of 0.8 μM .

HY-15142AS1

Doxorubicin-13C,d3 TFA Hydroxydaunorubicin-¹³C,d₃ TFA	Isotope-Labeled Compounds Antibiotic Endogenous Metabolite	Infection Cancer
Doxorubicin- ¹³C,d₃ (TFA) is the deuterium and ¹³C labeled Doxorubicin. Doxorubicin (Hydroxydaunorubicin), a cytotoxic anthracycline antibiotic, is an anti-cancer chemotherapy agent. Doxorubicin inhibits topoisomerase II with an IC50 of 2.67 μM, thus stoppin

HY-16261A

MC-DOXHZN (E/Z)-AlDoxorubicin; Doxorubicin(6-maleimidocaproyl)hydrazone	Topoisomerase Drug-Linker Conjugates for ADC	Cancer
MC-DOXHZN ((E/Z)-Aldoxorubicin) is an albumin-binding proagent of Doxorubicin (DNA topoisomerase II inhibitor), with acid-sensitive properties .

HY-16261B

MC-DOXHZN hydrochloride 5 Publications Verification (E/Z)-AlDoxorubicin hydrochloride; Doxorubicin(6-maleimidocaproyl)hydrazone hydrochloride	Topoisomerase Drug-Linker Conjugates for ADC	Cancer
MC-DOXHZN ((E/Z)-Aldoxorubicin) hydrochloride is an albumin-binding proagent of Doxorubicin (DNA topoisomerase II inhibitor), with acid-sensitive properties .

HY-121309S

Doxorubicinone-d3 Adriamycin aglycone-d₃; Adriamycinone-d₃	Endogenous Metabolite	Cancer
Doxorubicinone-d₃ is the deuterium labeled Doxorubicinone. Doxorubicinone is a metabolite of an anti-cancer chemotherapy agent Doxorubicin[1]. Doxorubicin is a potent human DNA topoisomerase I and topoisomerase II inhibitor with IC50s of 0.8 μM and 2.67 μM, respectively.

HY-121309

Doxorubicinone Adriamycin aglycone; Adriamycinone	Endogenous Metabolite	Cancer
Doxorubicinone is a metabolite of an anti-cancer chemotherapy agent Doxorubicin . Doxorubicin is a potent human DNA topoisomerase I and topoisomerase II inhibitor with IC₅₀s of 0.8 μM and 2.67 μM, respectively.

HY-G0022

Doxorubicinol hydrochloride

13-Dihydroadriamycin hydrochloride

Doxorubicinol hydrochloride (13-Dihydroadriamycin hydrochloride) is a secondary alcohol metabolite of Doxorubicin .

Doxorubicinol hydrochloride 13-Dihydroadriamycin hydrochloride
Doxorubicinol hydrochloride (13-Dihydroadriamycin hydrochloride) is a secondary alcohol metabolite of Doxorubicin .

HY-152965

Biotin-doxorubicin	Topoisomerase Antibiotic Apoptosis Autophagy	Infection Cancer
Biotin-doxorubicin is a Biotin-labeled Doxorubicin. Doxorubicin, a broad-spectrum anthracycline antibiotic, is a topoisomerase II inhibitor .

HY-136288

Azide-PEG4-VC-PAB-Doxorubicin	Drug-Linker Conjugates for ADC	Cancer
Azide-PEG4-VC-PAB-Doxorubicin is a agent-linker conjugate composed of a cytotoxic anthracycline antibiotic Doxorubicin and a linker Azide-PEG4-VC-PAB to make antibody agent conjugate (ADC) . Azide-PEG4-VC-PAB-Doxorubicin is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. Strain-promoted alkyne-azide cycloaddition (SPAAC) can also occur with molecules containing DBCO or BCN groups.

HY-16532

Zoptarelin doxorubicin AEZS-108; AN-152	GnRH Receptor	Cancer
Zoptarelin doxorubicin (AEZS-108; AN-152) is a hybrid anticancer agent, containing Zoptarelin and Doxorubicin. Zoptarelin doxorubicin has been used to research targeting tumors expressing LHRH receptors. Zoptarelin doxorubicin abolishes tumor progression and induces remarkable apoptosis in vitro .

HY-141158

N-(Iodoacetamido)-Doxorubicin

ADC Linker Cancer

N-(Iodoacetamido)-Doxorubicin is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs) .

N-(Iodoacetamido)-Doxorubicin	ADC Linker	Cancer
N-(Iodoacetamido)-Doxorubicin is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs) .

HY-15794

Nemorubicin Methoxymorpholinyl Doxorubicin; FCE 23762; PNU 152243	G-quadruplex	Cancer
Nemorubicin (Methoxymorpholinyl doxorubicin) is a Doxorubicin derivative with potent antitumor activity. Nemorubicin is highly cytotoxic to a variety of tumor cell lines presenting a multidrug-resistant phenotype. Nemorubicin not only intercalate into the duplex DNA, but also result in significant ligands for G-quadruplex DNA segments, stabilizing their structure. Nemorubicin requirs an intact nucleotide excision repair (NER) system to exert its activity .

HY-15794G

Nemorubicin Methoxymorpholinyl Doxorubicin; FCE 23762; PNU 152243	G-quadruplex	Cancer
Nemorubicin (Methoxymorpholinyl doxorubicin) GMP is a GMP-class Nemorubicin (HY-15794). Nemorubicin is a Doxorubicin derivative with potent antitumor activity. Nemorubicin is highly cytotoxic to a variety of tumor cell lines presenting a multidrug-resistant phenotype. Nemorubicin not only intercalate into the duplex DNA, but also result in significant ligands for G-quadruplex DNA segments, stabilizing their structure. Nemorubicin requirs an intact nucleotide excision repair (NER) system to exert its activity .

HY-154797

N,N-Dimethyldoxorubicin	Others	Cancer
N,N-Dimethyldoxorubicin is a Doxorubicin (HY-15142A) analogue. N,N-Dimethyldoxorubicin shows cytotoxicity against a panel of tumor cell lines (IC₅₀s < 0.3 μM) .

HY-W067427

BAY32-5915

IKK Cancer

BAY32-5915 is a potent IKKα inhibitor with an IC₅₀ value of 60 nM. BAY32-5915 has not affect Doxorubicin (HY-15142A)-induced NF-κB activation .

BAY32-5915	IKK	Cancer
BAY32-5915 is a potent IKKα inhibitor with an IC₅₀ value of 60 nM. BAY32-5915 has not affect Doxorubicin (HY-15142A)-induced NF-κB activation .

HY-P99630

Gancotamab MM-302	EGFR	Cancer
Gancotamab (MM-302) is a HER2-targeted antibody-liposomal Doxorubicin conjugate with antitumor activity. Gancotamab encapsulates Doxorubicin to facilitate its delivery to HER2-overexpressing tumor cells .

HY-119823

PGP-4008	P-glycoprotein	Cancer
PGP-4008 is a specific P-glycoprotein (Pgp) inhibitor. PGP-4008 inhibits tumor growth in a murine syngeneic Pgp-mediated multiple agent resistance (MDR) solid tumor model when given in combination with Doxorubicin .

HY-B0006B

(S)-Carvedilol (S)-BM 14190	Adrenergic Receptor	Cardiovascular Disease
(S)-Carvedilol, the S-enantiomer of Carvedilol, is a non-selective β/α-1 blocker. (S)-Carvedilol exerts protection against the vascular or cardiac toxicity of Doxorubicin (DOX) .

HY-B0006C

(R)-Carvedilol (R)-BM 14190	Adrenergic Receptor	Cardiovascular Disease
(R)-Carvedilol ((R)-BM 14190), the R-enantiomer of Carvedilol, is a non-selective β/α-1 blocker. (R)-Carvedilol exerts protection against the vascular or cardiac toxicity of Doxorubicin (DOX) .

HY-N10563

Coleon-U-quinone	P-glycoprotein	Cancer
Coleon-U-quinone is a potent P-gp inhibitor. Coleon-U-quinone can inhibit cancer cells viability and sensitize multidrug resistance cancer cells to Doxorubicin (HY-15142A) .

HY-15434A

NG25 trihydrochloride	MAP3K MAP4K	Cancer
NG25 trihydrochloride is a dual TAK1 and MAP4K2 inhibitor (IC₅₀: 149 nM and 21.7 nM respectively). NG25 sensitizes the breast cancer cells to Doxorubicin (HY-15142A), and enhances apoptosis. NG25 trihydrochloride can be used for research of various cancers .

HY-144769

SDOX	Topoisomerase	Cancer
SDOX is the Doxorubicin (DOX) proagent. The loaded DOX proagents (SDOX) which can release the parent agents DOX triggered by excessive GSH in tumor cells, minimize the unexpected side effects on normal tissues without compromising the potency .

HY-150650

S07-2001	Others	Cancer
S07-2001 is a potent and selective aldo-keto reductase 1C3 (AKR1C3) inhibitor with an IC₅₀ value of 2.08 μM. S07-2001 enhances the activity of Doxorubicin against cancer cells. S07-2001 has potential as a chemotherapeutic potentiator for cancer agent resistance .

HY-N3486

Isodunnianol	Autophagy	Cardiovascular Disease
Isodunnianol is a autophagy inducer. Isodunnianol induces autophagy and increases he expression of pAMPK172, pULK1555,decreases teh expression of pULK1757, SQSTM2. Isodunnianol decreases Doxorubicin (HY-15142A)-induced cardiotoxicity .

HY-145427

NU5455	DNA-PK	Cancer
NU5455 is a potent, selective, and orally active inhibitor of DNA-PKcs. NU5455 administration increases both the efficacy and the toxicity of a parenterally administered topoisomerase inhibitor. NU5455 enhances the activity of Doxorubicin released locally in liver tumor xenografts without inducing any adverse effect .

HY-N144114

P-gp inhibitor 2	P-glycoprotein	Cancer
P-gp inhibitor 2 is a potent P-gp inhibitor. P-gp inhibitor 2 shows reverse Doxorubicin resistance (IC₅₀=0.22 µM) in P-gp overexpressing human colorectal carcinoma cells (SW600 Ad300) .

HY-N10564

8α,9α-Epoxycoleon-U-quinone	P-glycoprotein	Cancer
8α,9α-Epoxycoleon-U-quinone (compound 3) is a p-glycoprotein (P-gp) regulator that is selective for cancer cells (SI=2.0). 8α,9α-Epoxycoleon-U-quinone effectively inhibits P-gp activity in NCI-H460/R cells. 8α,9α-Epoxycoleon-U-quinone also reverses the resistance of cancer cells to Doxorubicin (DOX) (HY-15142A) and enhances the anticancer effect of DOX .

HY-17507

Pantoprazole 3 Publications Verification BY1023; SKF96022	Proton Pump Autophagy Apoptosis Bacterial	Inflammation/Immunology Cancer
Pantoprazole (BY10232) is an orally active and potent proton pump inhibitor (PPI) . Pantoprazole, a substituted benzimidazole, is a potent H ⁺/K ⁺-ATPase inhibitor with an IC₅₀ of 6.8 μM. Pantoprazole improves pH stability and has anti-secretory, anti-ulcer activities. Pantoprazole significantly increased tumor growth delay combined with Doxorubicin (HY-15142) .

HY-17507A

Pantoprazole sodium 3 Publications Verification BY1023 sodium; SKF96022 sodium	Proton Pump Autophagy Apoptosis Bacterial	Inflammation/Immunology Cancer
Pantoprazole sodium (BY10232 sodium) is an orally active and potent proton pump inhibitor (PPI) . Pantoprazole sodium, a substituted benzimidazole, is a potent H ⁺/K ⁺-ATPase inhibitor with an IC₅₀ of 6.8 μM. Pantoprazole sodium improves pH stability and has anti-secretory, anti-ulcer activities. Pantoprazole sodium significantly increased tumor growth delay combined with Doxorubicin (HY-15142) .

HY-17507B

Pantoprazole sodium hydrate 3 Publications Verification BY1023 sodium hydrate; SKF96022 sodium hydrate	Proton Pump Autophagy Apoptosis Bacterial	Inflammation/Immunology Cancer
Pantoprazole sodium hydrate (BY10232 sodium hydrate) is an orally active and potent proton pump inhibitor (PPI) . Pantoprazole sodium hydrate, a substituted benzimidazole, is a potent H ⁺/K ⁺-ATPase inhibitor with an IC₅₀ of 6.8 μM. Pantoprazole sodium hydrate improves pH stability and has anti-secretory, anti-ulcer activities. Pantoprazole sodium hydrate significantly increased tumor growth delay combined with Doxorubicin (HY-15142) .

HY-Y1832

o-Vanillin 3-Methoxysalicylaldehyde	Fungal	Infection Cancer
o-Vanillin (2-Vanillin) is a nature product, could be extracted from Vanilla planifolia, Pinus koraiensis fruit. o-Vanillin is a potent antifungal agent. o-Vanillin inhibits the growth of mycelia by disrupting the integrity of cell walls and cell membranes. o-Vanillin inhibits Doxorubicin (HY-15142A)- and 4-hydroperoxycyclophosphamide-induced NF-κB activation .

HY-13745

Sabarubicin MEN 10755	Topoisomerase	Cancer
Sabarubicin is a doxorubicin disaccharide analogue with striking antitumor activity. Sabarubicin is more effective than doxorubicin as a topoisomerase II poison and stimulated DNA fragmentation at lower intracellular concentrations.

HY-153797

Dox-btn2	ADC Cytotoxin Antibiotic Bacterial Topoisomerase AMPK HIV HBV Apoptosis Autophagy Mitophagy	Infection Cancer
Dox-btn2 is a biotinylated derivative of Doxorubicin (HY-15142A), with a biotin label at the point of conjugation to doxorubicin at 3'-NH₂. Dox-btn2 can be used for cell imaging. While Doxorubicin is mainly accumulated in the nucleus, while Dox-btn2 is mainly located in the cytoplasm .

HY-162324

MX106-4C	Survivin	Cancer
MX106-4C is a survivin inhibitor that selectively kills ABCB1-positive colorectal cancer cells. MX106-4C can exert synergistic anticancer effects with Doxorubicin or resensitize drug-resistant ABCB1 cells to Doxorubicin .

HY-122182

OTS193320	Histone Methyltransferase Apoptosis	Cancer
OTS193320, a imidazo[1,2-a]pyridine compound, is a SUV39H2 methyltransferase activity inhibitor. OTS193320 decreases global histone H3 lysine 9 tri-methylation levels in breast cancer cells and triggers apoptotic cell death. Combination of OTS193320 with Doxorubicin (DOX; HY-15142A) results in reduction of γ-H2AX levels as well as cancer cell viability compared to a single agent OTS193320 or DOX .

HY-147968

Anticancer agent 74

Others Cancer

Anticancer agent 74 is a moderate anticancer agent. Anticancer agent 74 has lower selectivity and cytotoxicity than doxorubicin to normal cell .

Anticancer agent 74	Others	Cancer
Anticancer agent 74 is a moderate anticancer agent. Anticancer agent 74 has lower selectivity and cytotoxicity than doxorubicin to normal cell .

HY-N2591

Isocorydine	Endogenous Metabolite	Cancer
Isocorydine is isolated from Dicranostigma leptopodum (Maxim.) Fedde (DLF). Isocorydine combines with Doxorubicin (DOX) has a promising potential to eradicate hepatocellular carcinoma (HCC) .

HY-N2591A

Isocorydine hydrochloride	Endogenous Metabolite	Cancer
Isocorydine hydrochloride is isolated from Dicranostigma leptopodum (Maxim.) Fedde (DLF). Isocorydine hydrochloride combines with Doxorubicin (DOX) has a promising potential to eradicate hepatocellular carcinoma (HCC) .

HY-P2004

FFAGLDD	MMP	Cancer
FFAGLDD is MMP9 selective cleavage peptides, which used for cytosolic delivery of Doxorubi-cin (DOX) and achieve temporally and spatially controlled slow drug delivery and release .

HY-157330

P-gp inhibitor 16	P-glycoprotein Apoptosis	Cancer
P-gp inhibitor 16 (compound 14) is a p-glycoprotein inhibitor. P-gp inhibitor 16 significantly increases Doxorubicin-induced apoptosis and shows anticancer effects .

HY-P2004A

FFAGLDD TFA	MMP	Cancer
FFAGLDD TFA is MMP9 selective cleavage peptides, which used for cytosolic delivery of Doxorubi-cin (DOX) and achieve temporally and spatially controlled slow drug delivery and release .

HY-N3674

Dalbergioidin	TGF-beta/Smad	Inflammation/Immunology
Dalbergioidin, a well-known anthocyanin, ameliorates doxorubicin-induced renal fibrosis by suppressing the TGF-β signal pathway. Dalbergioidin exhibits tyrosinase inhibitory activity with an IC₅₀ of 20 mM .

HY-157484

P-gp inhibitor 19	P-glycoprotein	Cancer
P-gp inhibitor 19 (Compound 6i) is a P-gp inhibitor. P-gp inhibitor 19 can inhibit the efflux of rhodamine 123 (HY-D0816) in P-gp-overexpressing leukemia cells K562/Dox and also restore the sensitivity of DOX-resistant cells .

HY-117071

Dabuzalgron Ro 115-1240	Adrenergic Receptor Apoptosis	Cardiovascular Disease Endocrinology
Dabuzalgron (Ro 115-1240) is an orally active and selective α-1A adrenergic receptor agonist for the treatment of urinary incontinence. Dabuzalgron protects against Doxorubicin-induced cardiotoxicity by preserving mitochondrial function .

HY-N1514

Ganoderenic acid B	P-glycoprotein	Cancer
Ganoderenic acid B is a lanostane-type triterpene isolated from Ganoderma lucidum. Ganoderenic acid B exhibits potent reversal effect on ABCB1-mediated multidrug resistance of HepG2/ADM cells to Doxorubicin .

HY-110067

VO-OHPic	PTEN Apoptosis Autophagy	Cardiovascular Disease Metabolic Disease Inflammation/Immunology Cancer
VO-OHPic is a reversible, noncompetitive and selective PTEN inhibitor with an IC₅₀ of 46 nM. VO-OHPic attenuates apoptosis, adverse cardiac remodeling, and pro-inflammatory M1 macrophages in doxorubicin-induced cardiomyopathy. VO-OHPic inhibits autophagy .

HY-146391

P-gp inhibitor 4	P-glycoprotein	Cancer
P-gp inhibitor 4 (Compound 8b) is a selective P-glycoprotein modulator with an EC₅₀ of 94 nM. P-gp inhibitor 4 increases agent transport across gastro-intestinal barrier and recovers doxorubicin toxicity in multidrug resistant cancer cells .

HY-14942A

Berubicin hydrochloride RTA 744; WP 744; WP 769 hydrochloride	Apoptosis	Cancer
Berubicin hydrochloride (RTA 744) is a Doxorubicin (HY-15142A) analogue. Berubicin hydrochloride triggers apoptosis and cell killing in NB cells by activating proapoptotic mediators. Berubicin hydrochloride has proapoptotic and anti-leukemia activities. Berubicin hydrochloride can be used for cancer research .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-15142

Doxorubicin hydrochloride Maximum Cited Publications 364 Publications Verification Hydroxydaunorubicin hydrochloride	Infection Quinones Structural Classification Microorganisms Classification of Application Fields Anthraquinones Source classification Disease Research Fields	Topoisomerase ADC Cytotoxin AMPK Autophagy Apoptosis HIV HBV Mitophagy Antibiotic Bacterial
Doxorubicin (Hydroxydaunorubicin) hydrochloride, a cytotoxic anthracycline antibiotic, is an anti-cancer chemotherapy agent. Doxorubicin hydrochloride is a potent human DNA topoisomerase I and topoisomerase II inhibitor with IC₅₀s of 0.8 μM and 2.67 μM, respectively. Doxorubicin hydrochloride reduces basal phosphorylation of AMPK and its downstream target acetyl-CoA carboxylase. Doxorubicin hydrochloride induces apoptosis and autophagy .

HY-15142A

*Doxorubicin* Hydroxydaunorubicin	Infection Quinones Structural Classification Microorganisms Classification of Application Fields Anthraquinones Source classification Phenols Polyphenols Disease Research Fields	ADC Cytotoxin Antibiotic Bacterial Topoisomerase AMPK HIV Autophagy Mitophagy Apoptosis HBV
Doxorubicin (Hydroxydaunorubicin), a broad-spectrum anthracycline antibiotic with cytotoxic properties, is an anti-cancer chemotherapy agent. Doxorubicin has fluorescence properties. Doxorubicin inhibits topoisomerase II with an IC₅₀ of 2.67 μM, thus stopping DNA replication. Doxorubicin reduces basal phosphorylation of AMPK and its downstream target acetyl-CoA carboxylase. Doxorubicin induces apoptosis and autophagy . Doxorubicin inhibits human DNA topoisomerase I with an IC₅₀ of 0.8 μM .

HY-121309

Doxorubicinone Adriamycin aglycone; Adriamycinone	Quinones Structural Classification Classification of Application Fields Anthraquinones Source classification Endogenous metabolite Disease Research Fields Cancer	Endogenous Metabolite
Doxorubicinone is a metabolite of an anti-cancer chemotherapy agent Doxorubicin . Doxorubicin is a potent human DNA topoisomerase I and topoisomerase II inhibitor with IC₅₀s of 0.8 μM and 2.67 μM, respectively.

HY-N10563

Coleon-U-quinone	Structural Classification Ketones, Aldehydes, Acids Labiatae Smallanthus uvedalia (Linnaeus) Mackenzie Plants	P-glycoprotein
Coleon-U-quinone is a potent P-gp inhibitor. Coleon-U-quinone can inhibit cancer cells viability and sensitize multidrug resistance cancer cells to Doxorubicin (HY-15142A) .

HY-N3486

Isodunnianol	Structural Classification Terpenoids Sesquiterpenes Source classification Illicium verum Hook. f. Illiciaceae Plants	Autophagy
Isodunnianol is a autophagy inducer. Isodunnianol induces autophagy and increases he expression of pAMPK172, pULK1555,decreases teh expression of pULK1757, SQSTM2. Isodunnianol decreases Doxorubicin (HY-15142A)-induced cardiotoxicity .

HY-N144114

P-gp inhibitor 2	Classification of Application Fields Disease Research Fields Cancer	P-glycoprotein
P-gp inhibitor 2 is a potent P-gp inhibitor. P-gp inhibitor 2 shows reverse Doxorubicin resistance (IC₅₀=0.22 µM) in P-gp overexpressing human colorectal carcinoma cells (SW600 Ad300) .

HY-N10564

8α,9α-Epoxycoleon-U-quinone	Structural Classification Ketones, Aldehydes, Acids Labiatae Smallanthus uvedalia (Linnaeus) Mackenzie Plants	P-glycoprotein
8α,9α-Epoxycoleon-U-quinone (compound 3) is a p-glycoprotein (P-gp) regulator that is selective for cancer cells (SI=2.0). 8α,9α-Epoxycoleon-U-quinone effectively inhibits P-gp activity in NCI-H460/R cells. 8α,9α-Epoxycoleon-U-quinone also reverses the resistance of cancer cells to Doxorubicin (DOX) (HY-15142A) and enhances the anticancer effect of DOX .

HY-N2591

Isocorydine	Alkaloids Structural Classification Monophenols other families Classification of Application Fields Source classification Phenols Plants Isoquinoline Alkaloids Disease Research Fields Cancer	Endogenous Metabolite
Isocorydine is isolated from Dicranostigma leptopodum (Maxim.) Fedde (DLF). Isocorydine combines with Doxorubicin (DOX) has a promising potential to eradicate hepatocellular carcinoma (HCC) .

HY-N2591A

Isocorydine hydrochloride	Structural Classification Alkaloids Classification of Application Fields Source classification Endogenous metabolite Isoquinoline Alkaloids Disease Research Fields Cancer	Endogenous Metabolite
Isocorydine hydrochloride is isolated from Dicranostigma leptopodum (Maxim.) Fedde (DLF). Isocorydine hydrochloride combines with Doxorubicin (DOX) has a promising potential to eradicate hepatocellular carcinoma (HCC) .

HY-N3674

Dalbergioidin	Structural Classification Leguminosae Source classification Phenols Polyphenols Plants Phaseolus vulgaris Linn.	TGF-beta/Smad
Dalbergioidin, a well-known anthocyanin, ameliorates doxorubicin-induced renal fibrosis by suppressing the TGF-β signal pathway. Dalbergioidin exhibits tyrosinase inhibitory activity with an IC₅₀ of 20 mM .

HY-N1514

Ganoderenic acid B	Triterpenes Structural Classification Human Gut Microbiota Metabolites Microorganisms Classification of Application Fields Terpenoids Source classification Polyporaceae Plants Endogenous metabolite Disease Research Fields Cancer	P-glycoprotein
Ganoderenic acid B is a lanostane-type triterpene isolated from Ganoderma lucidum. Ganoderenic acid B exhibits potent reversal effect on ABCB1-mediated multidrug resistance of HepG2/ADM cells to Doxorubicin .

HY-D0226

Quinizarin 1,4-Dihydroxyanthraquinone	Infection Quinones Structural Classification Classification of Application Fields Anthraquinones Source classification Phenols Polyphenols Plants Solanaceae Disease Research Fields Rhizophora mucronata Lam	DNA/RNA Synthesis Fungal
Quinizarin (1,4-Dihydroxyanthraquinone), a part of the anticancer agents such as Doxorubicin, Daunorubicin, and Adriamycin, interacts with DNA by intercalating mode (K_d=86.1 μM). Quinizarin is used as a fungicide and pesticide chemical and has shown the ability to inhibit tumor cell growth .

HY-N10642

Pedaliin 6''-acetate	Flavonoids Flavones Labiatae Dracocephalum tanguticum Maxim. Plants	Others
Pedaliin 6''-acetate (compound 10) is a natural product that can be isolated from Dracocephalum tanguticum. Pedaliin 6''-acetate shows antioxidative activity and cytoprotective effect on doxorubicin (DOX)-induced toxicity in H9c2 cardiomyocytes with an EC₅₀ value of 19.1 μM .

HY-N6635

trans-Nerolidol	Structural Classification Natural Products Source classification Celastraceae Celastrus angulatus Maxim. Plants	Fungal
trans-Nerolidol is a sesquiterpene alcohol. It can be isolated from f aerial parts of Warionia saharae ex Benth. trans-Nerolidol improves the anti-proliferative effect of Doxorubicin (HY-15142A) against intestinal cancer cells in vitro. trans-Nerolidol also has anti-fungal activity .

HY-N10595

Ladanetin-6-O-β-(6′′-O-acetyl)glucoside	Flavonoids Flavones Labiatae Dracocephalum tanguticum Maxim. Plants	Others
Ladanetin-6-O-β-(6′′-O-acetyl)glucoside is a flavonoid isolated from the whole plants of Dracocephalum tanguticum, with antioxidant ability. Flavonoids from Dracocephalum tanguticum show cardioprotective effects against Doxorubicin (HY-15142A)-induced toxicity in H9c2 cells .

HY-N10562

Mutabilol	Terpenoids Labiatae Smallanthus uvedalia (Linnaeus) Mackenzie Diterpenoids Plants	P-glycoprotein
Mutabilol (compound 1) is a potent p-glycoprotein (P-gp) regulator. Mutabilol is a nature product could be isolated from Plectranthus mutabilis leaves. Mutabilol increases the P-gp expression in NCI-H460/R cells .

HY-N1346

Robinin 1 Publications Verification	Structural Classification Flavonoids Classification of Application Fields Flavones Leguminosae Plants Vigna unguiculata Inflammation/Immunology Disease Research Fields	Toll-like Receptor (TLR) Apoptosis
Robinin is a flavonoid that can be extracted from the leaves of purple cowpea, inhibiting TGF-β, TLR4/NF-κB and TLR2-PI3k-AKT signaling pathways. Robinin exerts anti-inflammatory and anti-tumor effects. The combination of Robinin and Methotrexate (HY-14519) reduces inflammation in experimental arthritis, Robinin can decrease the Doxorubicin (HY-15142A) induced cardiac toxicity effect .

HY-13755

Sulforaphane 30+ Cited Publications	Structural Classification Natural Products other families Classification of Application Fields Source classification Plants Inflammation/Immunology Disease Research Fields	HDAC Keap1-Nrf2 Apoptosis Bcl-2 Family Caspase Reactive Oxygen Species
Sulforaphane is an orally active inducer of the Keap1/Nrf2/ARE pathway. Sulforaphane promotes the transcription of tumor-suppressing proteins and effectively inhibits the activity of HDACs. Through the activation of the Keap1/Nrf2/ARE pathway and further induction of HO-1 expression, Sulforaphane protects the heart. Sulforaphane suppresses high glucose-induced pancreatic cancer through AMPK-dependent signal transmission. Sulforaphane exhibits both anticancer and anti-inflammatory properties .

HY-13755A

(R)-Sulforaphane L-Sulforaphane	Structural Classification Natural Products other families Classification of Application Fields Source classification Plants Disease Research Fields Cancer	Keap1-Nrf2 Bcl-2 Family Caspase Reactive Oxygen Species NF-κB
(R)-Sulforaphane (L-Sulforaphane) is a orally active, potent inducer of the Keap1/Nrf2/ARE pathway, exhibiting antioxidant and anticancer activities. (R)-Sulforaphane primarily functions by upregulating phase II detoxifying enzymes in cells, aiding in the removal of carcinogens and combating oxidative stress. (R)-Sulforaphane is capable of modulating gene expression, influencing various signaling pathways, including Nrf2, NF-κB, and AP-1. (R)-Sulforaphane can be used in studies of tumor biology, antioxidant defense mechanisms, as well as inflammation and immune responses .

Cat. No.	Product Name	Chemical Structure

HY-15142AS1

Doxorubicin-13C,d3 TFA
Doxorubicin- ¹³C,d₃ (TFA) is the deuterium and ¹³C labeled Doxorubicin. Doxorubicin (Hydroxydaunorubicin), a cytotoxic anthracycline antibiotic, is an anti-cancer chemotherapy agent. Doxorubicin inhibits topoisomerase II with an IC50 of 2.67 μM, thus stoppin

HY-121309S

Doxorubicinone-d3
Doxorubicinone-d₃ is the deuterium labeled Doxorubicinone. Doxorubicinone is a metabolite of an anti-cancer chemotherapy agent Doxorubicin[1]. Doxorubicin is a potent human DNA topoisomerase I and topoisomerase II inhibitor with IC50s of 0.8 μM and 2.67 μM, respectively.

HY-B0006BS

(S)-Carvedilol-d4
(S)-Carvedilol-d₄ is deuterium labeled (S)-Carvedilol. (S)-Carvedilol, the S-enantiomer of Carvedilol, is a non-selective β/α-1 blocker. (S)-Carvedilol exerts protection against the vascular or cardiac toxicity of Doxorubicin (DOX)[1].

HY-B0006CS

(R)-Carvedilol-d4
(R)-Carvedilol-d₄ is deuterium labeled (R)-Carvedilol. (R)-Carvedilol ((R)-BM 14190), the R-enantiomer of Carvedilol, is a non-selective β/α-1 blocker. (R)-Carvedilol exerts protection against the vascular or cardiac toxicity of Doxorubicin (DOX)[1].

HY-17507S

Pantoprazole-d6

Pantoprazole-d₆ is deuterium labeled Pantoprazole. Pantoprazole (BY10232) is an orally active and potent proton pump inhibitor (PPI)[1]. Pantoprazole, a substituted benzimidazole, is a potent H+/K+-ATPase inhibitor with an IC50 of 6.8 μM. Pantoprazole improves pH stability and has anti-secretory, anti-ulcer activities. Pantoprazole significantly increased tumor growth delay combined with Doxorubicin (HY-15142)[3][4].

HY-17507S1

Pantoprazole-d3

Pantoprazole-d₃ is deuterium labeled Pantoprazole. Pantoprazole (BY10232) is an orally active and potent proton pump inhibitor (PPI)[1]. Pantoprazole, a substituted benzimidazole, is a potent H+/K+-ATPase inhibitor with an IC50 of 6.8 μM. Pantoprazole improves pH stability and has anti-secretory, anti-ulcer activities. Pantoprazole significantly increased tumor growth delay combined with Doxorubicin (HY-15142)[3][4].

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks